Protecting Axons
Protecting Patients

Creating breakthrough therapeutics for neurological diseases

Disarm is conducting a chemotherapy-induced peripheral neuropathy (CIPN) natural history study (EPIPHANY). This prospective observational study is being conducted across multiple sites in the U.S. and will characterize CIPN disease course and associated biomarkers.

Learn More +

Disarm Therapeutics Appoints Veteran Biotech Executive Scott Holmes as Chief Financial Officer

January 13, 2020

press release

+

Axons Matter: The Promise of Treating Neurodegenerative Disorders by Targeting SARM1-Mediated Axonal Degeneration

February 24, 2020

publication

+

A New Approach to Treating Multiple Sclerosis

News

+